Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q10 for Hepatic Fat in Mitochondrial Diabetes
NCT07748130Not yet recruiting
- Sponsor
- The 95th Hospital of Putian
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Open-label trial of Coenzyme Q10 mucoadhesive tablets in maternally inherited diabetes and deafness (MIDD) and hepatic steatosis (3 arms), sponsored by The 95th Hospital of Putian. Primary endpoint: Liver Fat Quantification at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Coenzyme Q10 mucoadhesive tablets
03
Conditions
maternally inherited diabetes and deafness (MIDD)hepatic steatosis
Beyond the preview
Go deeper on NCT07748130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748130.